公开(公告)号：WO2007081868A9

公开(公告)日：2007-09-07

申请号：PCT/US2007000389

申请日：2007-01-05

Applicant: ABBOTT LAB ,  SPRING THOMAS G ,  BRATE ELAINE M ,  HOLETS-MCCORMACK SHELLEY ,  REDDY RAJARATHNAM E ,  JOHNSON DONALD D ,  CHEN YON-YIH ,  PAN YOU

Inventor： SPRING THOMAS G ,  BRATE ELAINE M ,  HOLETS-MCCORMACK SHELLEY ,  REDDY RAJARATHNAM E ,  JOHNSON DONALD D ,  CHEN YON-YIH ,  PAN YOU

IPC: G01N33/94

CPC classification number: G01N33/9493

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.

Abstract translation: 用于通过免疫测定法，优选竞争性免疫测定法测量生物样品中FK778浓度的方法和试剂盒。 在一个方面，所述方法和试剂盒涉及使用（a）缀合至标记物（例如吖啶鎓标记物）的FK778的抗体，（b）未缀合至标记物的FK778抗体，（c）含有 （d）包含第一半抗原和FK778或FK778类似物的二连胜肽，例如包含荧光素半抗原和FK778半抗原的二连胜蛋白。 另一方面，所述方法和试剂盒涉及使用（a）FK778抗体，（b）包含FK778或FK778类似物的二连胜蛋白和第一半抗原，例如包含荧光素半抗原和FK778的半抗原的二连蛋白，或 FK778的类似物，和（c）预处理试剂。

公开(公告)号：CO6491043A2

公开(公告)日：2012-07-31

申请号：CO12005568

申请日：2012-01-16

Applicant: ABBOTT LAB

Inventor： CHEMBURKAR SANJAY R ,  REDDY RAJARATHNAM E ,  REAMER DOUGLAS M ,  PAVLINA JOHN T ,  ULREY STEPHEN S ,  KOTECKI BRIAN

IPC: C07D209/42

Abstract: La presente invención se relaciona con un procedimiento estereoespecífico mejorado para la fabricación de ácido (2S, 3aR, 7aS)-octahidro-1H-indol-2-carboxílico en forma de sal de clorhidrato, un intermediario clave en la preparación de trandolapril. La N-alquilación selectiva de (1S, 2S)-2-[(S)-1-feniletil amino]ciclohexil) metanol con bromoacetato de etilo se realizó con bicarbonato de sodio en acetonitrilo para dar la funcionalidad de hidroxilo en el compuesto se convierte entonces en éster de metanosulfonato para producir el compuesto. El trandolapril es un profármaco éster etílico de trandolaprilat para controlar y tratar la hipertensión. Funciona como un inhibidor de la Enzima Convertidora de Angiotensina, lo que resulta en la reducción de la presión arterial y es útil para el tratamiento de la insuficiencia cardíaca. El trandolapril puede usarse solo como medicamento oral. Alternativamente, se puede utilizar combinado con Verapamil, un antagonista del calcio o con diuréticos.

公开(公告)号：AU2011215616A1

公开(公告)日：2012-09-06

申请号：AU2011215616

申请日：2011-02-14

Applicant: ABBOTT LAB

Inventor： REDDY RAJARATHNAM E ,  CHEMBURKAR SANJAY R ,  SPAULDING DOUGLAS R ,  PAN YI ,  CAO LEI ,  RESTITUYO JOSE A ,  LORENZINI RICHARD ,  DEMARCO MICHAEL

IPC: C07C35/16 ,  C07H1/06

Abstract: This invention pertains to a process for manufacturing scyllo-Inositol. Specifically, the current invention pertains to a process for converting -Inositol to -Inositol using a bioconversion process.

公开(公告)号：CA2636377A1

公开(公告)日：2007-07-19

申请号：CA2636377

申请日：2007-01-05

Applicant: ABBOTT LAB

Inventor： CHEN YON-YIH ,  JOHNSON DONALD D ,  BRATE ELAINE M ,  SPRING THOMAS G ,  REDDY RAJARATHNAM E ,  PAN YOU ,  HOLETS-MCCORMACK SHELLEY

IPC: G01N33/94

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.